Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740663 | 0.88 | ALDH1A1 (0.39) | ALDH1A1GAAKMT2APOLBCYP1A1 | |
| SCHEMBL23360887 | 0.86 | NQO2 (0.41) | ALDH1A1GAAKMT2APOLBNPC1 | |
| SCHEMBL21337861 | 0.86 | HTR6 (0.50) | ALDH1A1GAAKMT2APOLBCYP1A1 | |
| SCHEMBL5457585 | 0.82 | HDAC3 (0.47) | NPC1KDM4E | |
| SCHEMBL6754404 | 0.80 | MAPT (0.53) | ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29959920 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KMT2APOLBNPC1RAB9A | |
| SCHEMBL1188678 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KMT2APOLBNPC1RAB9A | |
| SCHEMBL16720275 | 0.78 | ALDH1A1 (0.35) | ALDH1A1GAAKMT2APOLBNPC1 | |
| SCHEMBL10430237 | 0.78 | SLC22A12 (0.42) | ALDH1A1KMT2ACYP1A1CYP1B1MEN1 | |
| SCHEMBL225907 | 0.77 | NPC1 (0.56) | ALDH1A1GAANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-3421457-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| CN-104961644-A | Method used for preparing N-aryl amide compound | UNIV SHANGHAI JIAOTONG | 2015-10-07 | — | — | CN | disclosed |
| EP-1146865-B9 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF DEXTRO- AND LAEVO- ISOMERS OF SOTALOL | TORRENT PHARMACEUTICALS LTD (IN) | 2004-03-17 | — | — | EP | disclosed |
| EP-1146865-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF DEXTRO- AND LAEVO- ISOMERS OF SOTALOL | TORRENT PHARMACEUTICALS LTD (IN) | 2003-05-28 | — | — | EP | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| EP-1146865-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF DEXTRO- AND LAEVO- ISOMERS OF SOTALOL | Torrent Pharmaceuticals Ltd (IN) | 2001-10-24 | — | — | EP | disclosed |
| US-6281246-B2 | CONTROLLING RATIOS OF ISOMERS | TORRENT PHARMACEUTICAL LTD. (IN) | 2001-08-28 | — | — | US | disclosed |
| US-20010004643-A1 | Pharmaceutical composition with sotalol combination and their use in treatment of cardiac ailments | THE ROSHNI SINGH 2015 TRUST | 2001-06-21 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000045807-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF DEXTRO- AND LAEVO- ISOMERS OF SOTALOL | SANKARANARAYANAN ALANGUDI (IN) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010004643-A1 | Pharmaceutical composition with sotalol combination and their use in treatment of cardiac ailments | ADRB1, ADRB2, ADRB3 | ALDH1A1 525/4885GAA 929/4885KMT2A 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.